Explore
Validate
LearnAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA001297 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA001297, RRID:AB_1078913
- Product name
- Anti-FRMD6
- Antibody type
- Polyclonal
- Description
- Affinity purified using the PrEST antigen as affinity ligand
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Antigen sequence
LEEDLQDDEIEMLVDDPRDLEQMNEESLEVSPDMC
IYITEDMLMSRKLNGHSGLIVKEIGSSTSSSSETV
VKLRGQSTDSLPQTICRKPKTSTDRHSLSLDDIRL
YQKDFLRIAGLCQDTAQSYTFGCGHELDEE- Isotype
- IgG
- Vial size
- 100 µl
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Submitted references Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer
PD-L1 as a Prognostic Factor in Early-Stage Colon Carcinoma within the Immunohistochemical Molecular Subtype Classification
Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer
Expression and regulation of FRMD6 in mouse DRG neurons and spinal cord after nerve injury
Early-stage serrated adenocarcinomas are divided into several molecularly distinct subtypes
Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions
Cheah P, Mochizuki K, Kudo S, Kato K, Kudo K, Ogawa Y, Kouyama Y, Takashina Y, Ichimasa K, Tobo T, Toshima T, Hisamatsu Y, Yonemura Y, Masuda T, Miyachi H, Ishida F, Nemoto T, Mimori K
PLOS ONE 2022;17(10):e0273566
PLOS ONE 2022;17(10):e0273566
PD-L1 as a Prognostic Factor in Early-Stage Colon Carcinoma within the Immunohistochemical Molecular Subtype Classification
Azcue P, Encío I, Guerrero Setas D, Suarez Alecha J, Galbete A, Mercado M, Vera R, Gomez-Dorronsoro M
Cancers 2021;13(8):1943
Cancers 2021;13(8):1943
Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer
Li Y, Yao Q, Zhang L, Mo S, Cai S, Huang D, Peng J
The Oncologist 2020;25(12):e1968-e1979
The Oncologist 2020;25(12):e1968-e1979
Expression and regulation of FRMD6 in mouse DRG neurons and spinal cord after nerve injury
Lyu C, Lyu G, Mulder J, Uhlén M, Cai X, Hökfelt T, Sten Shi T
Scientific Reports 2020;10(1)
Scientific Reports 2020;10(1)
Early-stage serrated adenocarcinomas are divided into several molecularly distinct subtypes
Katoh M, Hirano D, Urabe Y, Tanaka S, Nakamura K, Ninomiya Y, Yuge R, Hayashi R, Oka S, Kitadai Y, Shimamoto F, Arihiro K, Chayama K
PLOS ONE 2019;14(2):e0211477
PLOS ONE 2019;14(2):e0211477
Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions
De Sousa E Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij L, de Jong J, de Boer O, van Leersum R, Bijlsma M, Rodermond H, van der Heijden M, van Noesel C, Tuynman J, Dekker E, Markowetz F, Medema J, Vermeulen L
Nature Medicine 2013;19(5):614-618
Nature Medicine 2013;19(5):614-618
No comments: Submit comment
No validations: Submit validation data